In a research report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8.00 price target, …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8.00 price target, which …
In a research note released today, H.C.
Maxim Group analyst Jason Kolbert today maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8 price target, as the company announced that it has …
In a research note published yesterday, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) and an $8 price …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (PSTI) with a $8 price target, which represents a potential upside of 176% from …
